YLYunXia Liu

YunXia Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


YunXia Liu has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Applied theory of planned behavior to explore associated factor of physical activity level among Chinese childhood cancer survivors

    by Fengjiao Xu, Yiqing Weng, Danni Lv, Hui Zheng, Jieni Xiong, Li Zhang, Feng Lu, Xia Guo, Weisong Cai, Qian Wang, et al.

    Objective Low physical activity (PA) levels are common among childhood cancer survivors (CCS) and have a serious negative impact on their physical recovery and long-term health. This study aimed to explore the factors that contribute to low levels of PA from the perspective of children themselves and how these factors affect their PA. Methods In this cross-sectional survey, CCS were recruited by purposive sampling from several children’s medical centers nationwide. The online questionnaires, which involved three valid scales (the Godin Leisure-Time Exercise Questionnaire, Theory of Planned Behavior (TPB) construct, and Physical Activity Self-efficacy), were used for data collection from July 2021 to January 2023. The Wilcoxon rank-sum test, Chi-square or Fisher’s exact test, and logistic regression analysis were used to analyze the factors associated with PA in CCS. The associations between CCS’ PA level and cognitive variables (TPB construct and self-efficacy) were evaluated using path analysis. Results Among the 1350 eligible participants, ultimately 964 of them submitted valid questionnaires. According to the leisure time index (LSI) scores, 59.34% of Chinese CCS reached the recommendation level of moderate-vigorous physical activity (MVPA) (LSI ≥ 24). Attending school, diagnosis, time since discharge, behavioral intention, and self-efficacy were associated with MVPA levels in CCS. Path analysis showed that intention and self-efficacy exerted a direct effect on CCS’ PA, whereas the direct impact of perceived behavioral control on MVPA was not significant. The overall model fit indices of the TPB extended model incorporating self-efficacy showed the model fits the data well (RMSEA = 0.000, CFI = 1.000, NFI = 1.001, and TLI = 1.009). Conclusion Compared to healthy populations, the level of MVPA participation among Chinese CCS was relatively lower. Improving self-efficacy is essential for increasing participation in CCS’ physical activities. The extended TPB model with self-efficacy is appropriate for explaining MVPA participation in CCS. Implications for Cancer Survivors This study highlights the critical need to address low physical activity levels among childhood cancer survivors (CCS), as insufficient engagement in moderate-vigorous physical activity (MVPA) may hinder their recovery and longterm health outcomes. The findings underscore the pivotal role of self-efficacy in promoting MVPA participation, with both direct and indirect effects on activity behaviors. Interventions targeting CCS should prioritize strategies to enhance self-efficacy—such as goal-setting, skill-building, and psychosocial support—to foster sustained engagement in physical activity. Additionally, the validated extended theory of planned behavior (TPB) model provides a framework for designing tailored, survivor-centered programs that address behavioral, social, and environmental barriers. Clinicians and caregivers should adopt multidimensional approaches integrating self-efficacy enhancement, peer/community support, and accessible physical activity opportunities to mitigate long-term health risks and improve quality of life for CCS.


  • Open Access

    Data from First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial

    by Tao Li, Ying Dong, Yongzhong Wei, Shoufeng Wang, Yunxia Liu, Jia Chen, Wenhua Xiong, Nong Lin, Xin Huang, Meng Liu, et al.

    Purpose:Standard treatment for patients with unresectable locally advanced or metastatic soft-tissue sarcoma (LA/M STS) is chemotherapy based on anthracyclines, but patient tolerance of chemotherapy is limited. The present trial (NCT03792542) investigated the use of anlotinib as first-line treatment for patients with advanced STS, in particular liposarcoma.Patients and Methods:Eligible patients were previously untreated, pathologically confirmed, unresectable LA/M STS cases. Anlotinib was given orally at a dose of 12 mg once daily from days 1 to 14 every 3 weeks until disease progression or intolerable adverse events (AE) occurred. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate, and disease control rate (DCR). The safety profile was also evaluated.Results:Forty patients were enrolled from April 2019 to June 2022 and are included in the intention-to-treat analysis. The median PFS was 6.83 months [95% confidence interval (CI), 4.17–8.71] and the median OS 27.40 months (95% CI, 16.43–not evaluable); 1 patient reached partial response and 26 attained stable disease, with a DCR of 67.5% (27/40). Median PFS and OS times for liposarcoma patients were 8.71 and 16.23 months, respectively. Ten (25.0%) patients had treatment-related AEs ≥ grade 3, with in particular a higher incidence of hypertension (15.0%) and proteinuria (7.5%).Conclusions:The findings suggest a potential benefit in using front-line anlotinib to treat patients with STS, who are not eligible for cytotoxic chemotherapy. Of note, the clinical outcomes for the liposarcoma subgroup of patients were encouraging.See related commentary by Napolitano et al., p. 4257

  • Open Access

    Supplementary Data 1 from First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial

    by Tao Li, Ying Dong, Yongzhong Wei, Shoufeng Wang, Yunxia Liu, Jia Chen, Wenhua Xiong, Nong Lin, Xin Huang, Meng Liu, et al.

    Supplementary File 1. Inclusion and exclusion criteria.Supplementary Table S1. Representativeness of trial patients.Supplementary Table S2. Summary of adverse events.

  • Top Cited Papers
    Open Access

    First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial

    by Tao Li, Ying Dong, Yongzhong Wei, Shoufeng Wang, Yunxia Liu, Jia Chen, Wenhua Xiong, Nong Lin, Xin Huang, Meng Liu, et al.

    Purpose: Standard treatment for patients with unresectable locally advanced or metastatic soft-tissue sarcoma (LA/M STS) is chemotherapy based on anthracyclines, but patient tolerance of chemotherapy is limited. The present trial (NCT03792542) investigated the use of anlotinib as first-line treatment for patients with advanced STS, in particular liposarcoma. Patients and Methods: Eligible patients were previously untreated, pathologically confirmed, unresectable LA/M STS cases. Anlotinib was given orally at a dose of 12 mg once daily from days 1 to 14 every 3 weeks until disease progression or intolerable adverse events (AE) occurred. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate, and disease control rate (DCR). The safety profile was also evaluated. Results: Forty patients were enrolled from April 2019 to June 2022 and are included in the intention-to-treat analysis. The median PFS was 6.83 months [95% confidence interval (CI), 4.17–8.71] and the median OS 27.40 months (95% CI, 16.43–not evaluable); 1 patient reached partial response and 26 attained stable disease, with a DCR of 67.5% (27/40). Median PFS and OS times for liposarcoma patients were 8.71 and 16.23 months, respectively. Ten (25.0%) patients had treatment-related AEs ≥ grade 3, with in particular a higher incidence of hypertension (15.0%) and proteinuria (7.5%). Conclusions: The findings suggest a potential benefit in using front-line anlotinib to treat patients with STS, who are not eligible for cytotoxic chemotherapy. Of note, the clinical outcomes for the liposarcoma subgroup of patients were encouraging. See related commentary by Napolitano et al., p. 4257


  • Open Access

    Circular RNA hsa_circ_0051246 acts as a microRNA-375 sponge to promote the progression of gastric cancer stem cells via YAP1

    by Minghui Deng, Yefeng Xu, Yongwei Yao, Yiqing Wang, Qingying Yan, Miao Cheng, YunXia Liu

    Background: Gastric cancer (GC) stem cells play an important role in GC progression. Circular RNAs (circRNAs) act as microRNA (miRNA) sponges and inhibit the biological function of miRNAs in GC cytoplasm. MiRNAs also participate in GC progress. circ_0051246 was shown to be associated with miR-375 after analyzing GC microarray data GSE78091 and GSE83521. The oncoprotein Yes-associated protein 1 (YAP1) is targeted by miR-375 and can be inactivated via the Hippo tumor suppressor pathway. Due to insufficient research on circ_0051246, this study aimed to investigate its relationship with miR-375 and YAP1 in cancer stem cells (CSCs). Methods: SGC-7901 CSCs were used to establish knockdown/overexpression models of circ_0051246, miR-375, and YAP1. Malignant phenotypes of CSCs were assessed using Cell Counting Kit 8, colony/sphere formation, 5-Ethynyl-2′-deoxyuridine assay, flow cytometry, Transwell, and wound healing assays. To detect the interactions between circ_0051246, miR-375, and YAP1 in CSCs, a dual-luciferase reporter assay and fluorescence in situ hybridization were performed. In addition, 24 BALB/c nude mice were used to establish orthotopic xenograft tumor models. Four groups of mice were injected with CSCs (1 × 106 cells/100 µL) with circ_0051246 knockdown, miR-375 overexpression, or their respective control cells, and tumor progression and gene expression were observed by hematoxylin-eosin staining, immunohistochemistry. Western blot and quantitative real-time PCR were utilized to examine protein and gene expression, respectively. Results: Circ_0051246 silencing reduced viability, promoted apoptosis, and inhibited proliferation, migration and invasion of CSCs. The functional effects of miR-375 mimics were comparable to those of circ_0051246 knockdown; however, the opposite was observed after miR-375 inhibitors treatment of CSCs. Furthermore, circ_0051246-overexpression antagonized the miR-375 mimics’ effects on CSCs. Additionally, YAP1 overexpression promoted CSC features, such as self-renewal, migration, and invasion, inhibited apoptosis and E-cadherin levels, and upregulated the expression of N-cadherin, vimentin, YAP1, neurogenic locus notch homolog protein 1, and jagged canonical notch ligand 1. Conversely, YAP1-silenced produced the opposite effect. Moreover, miR-375 treatment antagonized the malignant effects of YAP1 overexpression in CSCs. Importantly, circ_0051246 knockdown and miR-375 activation suppressed CSC tumorigenicity in vivo. Conclusion: This study highlights the promotion of circ_0051246-miR-375-YAP1 axis activation in GC progression and provides a scientific basis for research on the molecular mechanism of CSCs.


  • Open Access

    Pharmacological Mechanism of Sancao Yuyang Decoction in the Treatment of Oral Mucositis Based on Network Pharmacology and Experimental Validation

    by Yunxia Liu, Yun Ye, Guanqun Xie, Yefeng Xu, Miao Cheng, Chunling Li, Mengqi Qu, Feiye Zhu

    Purpose: The network pharmacology analysis, molecular docking and experimental verification were performed to explore the pharmacological mechanisms of Sancao Yuyang Decoction (SCYYD) in the treatment of oral mucositis (OM). Methods: Active ingredients in SCYYD and their potential targets, as well as OM-related targets were screened from public databases. The core targets and signaling pathways of SCYYD against OM were determined by protein–protein interaction (PPI) network, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. The ingredient-target-disease network and target-pathway network were constructed. Subsequently, molecular docking was carried out to predict the binding activity between active ingredients and key targets. Moreover, in vivo experiment was conducted to further verify the core targets predicted by network pharmacology analysis. Results: A total of 119 bioactive ingredients were screened from the corresponding databases. One hundred and eighty-six putative targets were retrieved and bioinformatics analysis was performed to reveal the top 5 potential candidate agents and 10 core targets. GO and KEGG enrichment analysis showed that SCYYD exerted excellent therapeutic effects on OM through several pathways, such as HIF-1 and Ras signaling pathway. Subsequently, molecular docking showed that main ingredients in SCYYD had optimal binding activities to the key protein targets. Moreover, the result of in vivo experiment indicated that SCYYD not only inhibited inflammation response and promoted wound healing of oral mucosa in OM rats, but also reversed high expressions of SRC, HSP90AA1, STAT3, HIF1α, mTOR, TLR4, MMP9, and low expression of ESR1. Conclusion: This study preliminarily uncovered the multiple compounds and multiple targets of SCYYD against OM using network pharmacology, molecular docking and in vivo verification, which provided a new insight of the pharmacological mechanisms of SCYYD in treatment of OM.


  • Open Access

    Soothing liver-qi stagnation method for cancer-related depression

    by Jianfeng Mm Zhang, Yunxia Liu, Yefeng Mm Xu

    Background: Cancer-related depression (CRD) is the most common mood disorder in patients with malignant tumors, negatively influencing the patient's daily life. Traditional Chinese medicine, as an alternative CRD therapy, has shown good treatment performance in recently years. Soothing liver-qi stagnation, as a classic therapy for depression, is based on traditional Chinese medicine theory. However, there is no evidence-based medical confirmation for the soothing liver-qi stagnation method for CRD treatment. Methods: We will systematically search relevant articles from their inception to July 1, 2019 in the following electronic databases: the Cochrane Library, PubMed, EMBASE, Chinese National Knowledge Infrastructure Database, Chinese Biomedical Literature Database, Chinese Science and Technique Journals Database, and the Wan-fang Database. The primary outcome is the total scores of the Hamilton rating scale for depression and, the efficacy rate of reducing Hamilton rating scale for depression scores. The secondary outcomes are adverse reactions and quality of life as assessed by standard instruments. Two researchers will independently perform study selection, data extraction, and quality assessment. If there is any disagreement, it will be settled through third-party negotiations. We will assess the risk of bias and data synthesis using Review Manager (the Cochrane Collaboration) software, Version 5.3.0. Results: This work will evaluate the clinical effectiveness and safety of the soothing liver-qi stagnation method for CRD. Conclusion: This study may provide evidence-based medical corroboration for clinical application of the soothing liver-qi stagnation method for CRD treatment. PROSPERO registration number: CRD42019145678.


  • Open Access

    Comprehensive Analysis of a circRNA-miRNA-mRNA Network to Reveal Potential Inflammation-Related Targets for Gastric Adenocarcinoma

    by YunXia Liu, YeFeng Xu, Feng Xiao, JianFeng Zhang, YiQing Wang, YongWei Yao, JieWen Yang

    Gastric cancer (GC) is the most common malignancy of the stomach. This study was aimed at elucidating the regulatory network of circRNA-miRNA-mRNA and identifying the precise inflammation-related targets in GC. The expression profiles of GSE83521, GSE78091, and GSE33651 were obtained from the GEO database. Interactions between miRNAs and circRNAs were investigated by the Circular RNA Interactome, and targets of miRNAs were predicted with miRTarBase. Then, a circRNA/miRNA/mRNA regulatory network was constructed. Also, functional enrichment analysis of selected differentially expressed genes (DEGs) was performed. The inflammation-/GC-related targets were collected in the GeneCards and GenLiP3 database, respectively. And a protein-protein interaction (PPI) network of DE mRNAs was constructed with STRING and Cytoscape to identify hub genes. The genetic alterations, neighboring gene networks, expression levels, and the poor prognosis of hub genes were investigated in cBioPortal, Oncomine, and Human Protein Atlas databases and Kaplan-Meier plotter, respectively. A total of 10 DE miRNAs and 33 DEGs were identified. The regulatory network contained 26 circRNAs, 10 miRNAs, and 1459 mRNAs. Functional enrichment analysis revealed that the selected 33 DEGs were involved in negative regulation of fat cell differentiation, response to wounding, extracellular matrix- (ECM-) receptor interaction, and regulation of cell growth pathways. THBS1, FN1, CALM1, COL4A1, CTGF, and IGFBP5 were selected as inflammation-related hub genes of GC in the PPI network. The genetic alterations in these hub genes were related to amplification and missense mutations. Furthermore, the genes RYR2, ERBB2, PI3KCA, and HELZ2 were connected to hub genes in this study. The hub gene levels in clinical specimens were markedly upregulated in GC tissues and correlated with poor overall survival (OS). Our results suggest that THBS1, FN1, CALM1, COL4A1, CTGF, and IGFBP5 were associated with the pathogenesis of gastric carcinogenesis and may serve as biomarkers and inflammation-related targets for GC.


  • Associations between interleukin gene polymorphisms and the risk of gastric cancer: A meta‐analysis

    by Yunxia Liu, Yefeng Xu, Yiqing Wang, Yongwei Yao, Jiewen Yang

    Summary: Recently, the roles of interleukin‐2 (IL‐2),IL‐4,IL‐6andIL‐8gene polymorphisms in gastric cancer (GC) have been studied extensively, with conflicting results. Therefore, we conducted the present meta‐analyses to better elucidate the roles of interleukin gene polymorphisms inGC. Eligible articles were searched in PubMed, MEDLINE, Embase, Web of Science andCNKI. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to detect any potential association between interleukin gene polymorphisms and the risk ofGC. A total of 63 case‐control studies was finally included in our analyses. Significant associations with the risk ofGCwere detected for theIL‐6rs1800796 andIL‐8rs4073 polymorphisms in overall analyses. Further subgroup analyses based on ethnicities of participants revealed that theIL‐4rs2243250,IL‐6rs1800796 andIL‐8rs4073 polymorphisms were significantly associated with the risk ofGCin Asians. Moreover,IL‐8rs4073 polymorphism was also significantly associated with the risk ofGCin Africans. In conclusion, our findings suggested thatIL‐4rs2243250,IL‐6rs1800796 andIL‐8rs4073 polymorphisms may serve as genetic biomarkers ofGC.


    • 1 January 2017
      • Vol. 21  (1) , 120-130

    The diagnostic and prognostic values of microRNA-21 in patients with gastric cancer: a meta-analysis

    by J. Ren, T. -H. Kuang, J. Chen, J. -W. Yang, Y. -X. Liu

    OBJECTIVE: Previous studies demonstrated the pivotal role of miR-21 in the pathogenesis and progression of gastric cancer. This meta-analysis was designed to confirm the diagnostic and prognostic value of microRNA-21 (miR-21) in gastric cancer and to investigate the influence of samples on the results of miR-21 detection. MATERIALS AND METHODS: A literature search was conducted in PubMed and Embase databases up to August 2016. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the summary receiver-operating characteristic (AUC) were calculated by Meta-Disc (version 14.0) or RevMan 5.3 software. RESULTS: Ten studies including 516 patients with gastric cancer and 239 healthy controls were selected. Pooled sensitivity (0.74, 95% CI: 0.69-0.79), specificity (0.81, 95% CI: 0.76-0.86), PLR (3.85, 95% CI: 3.00-4.94), NLR (0.22, 95% CI: 0.31-0.45), and DOR (13.07, 95% CI: 8.81-19.39) as well as AUC (0.8561 +/- 0.0204) indicated the good diagnostic accuracy of miR-21 in detecting gastric cancer. The prognostic value of miR-21 for lymph node metastasis in gastric cancer was also demonstrated by the pooled sensitivity (0.56, 95% CI: 0.48-0.64), specificity (0.62, 95% CI: 0.53-0.71), PLR (2.02, 95% CI: 0.90-4.54), NLR (0.58, 95% CI: 0.45-0.75), and DOR (3.50, 95% CI: 1.04-11.83) as well as AUC (0.6673 +/- 0.0469). Subgroup analyses showed that the samples used to detect miR-21 were the source of heterogeneity could affect the diagnostic or prognostic value of miR-21 in gastric cancer. CONCLUSIONS: miR-21 can be used for the diagnosis of gastric cancer and prognosis of lymph node metastasis in gastric cancer.